220 related articles for article (PubMed ID: 23359319)
1. Genome-wide association study identifies loci at ATF7IP and KLK2 associated with percentage of circulating free PSA.
Jin G; Zheng SL; Lilja H; Kim ST; Tao S; Gao Z; Young T; Wiklund F; Feng J; Isaacs WB; Rittmaster RS; Gronberg H; Condreay LD; Sun J; Xu J
Neoplasia; 2013 Jan; 15(1):95-101. PubMed ID: 23359319
[TBL] [Abstract][Full Text] [Related]
2. Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml.
Haese A; Graefen M; Steuber T; Becker C; Pettersson K; Piironen T; Noldus J; Huland H; Lilja H
Prostate; 2001 Oct; 49(2):101-9. PubMed ID: 11582588
[TBL] [Abstract][Full Text] [Related]
3. Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater.
Becker C; Piironen T; Pettersson K; Hugosson J; Lilja H
Urology; 2000 May; 55(5):694-9. PubMed ID: 10792083
[TBL] [Abstract][Full Text] [Related]
4. Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer.
Becker C; Piironen T; Pettersson K; Hugosson J; Lilja H
J Urol; 2003 Oct; 170(4 Pt 1):1169-74. PubMed ID: 14501718
[TBL] [Abstract][Full Text] [Related]
5. Genetic variation in KLK2 and KLK3 is associated with concentrations of hK2 and PSA in serum and seminal plasma in young men.
Sävblom C; Halldén C; Cronin AM; Säll T; Savage C; Vertosick EA; Klein RJ; Giwercman A; Lilja H
Clin Chem; 2014 Mar; 60(3):490-9. PubMed ID: 24270797
[TBL] [Abstract][Full Text] [Related]
6. Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum.
Steuber T; Vickers AJ; Haese A; Becker C; Pettersson K; Chun FK; Kattan MW; Eastham JA; Scardino PT; Huland H; Lilja H
Int J Cancer; 2006 Mar; 118(5):1234-40. PubMed ID: 16152616
[TBL] [Abstract][Full Text] [Related]
7. Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen.
Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Huber A; Lümmen G; Tscholl R
Urology; 2000 Apr; 55(4):481-5. PubMed ID: 10736487
[TBL] [Abstract][Full Text] [Related]
8. A comprehensive resequence analysis of the KLK15-KLK3-KLK2 locus on chromosome 19q13.33.
Parikh H; Deng Z; Yeager M; Boland J; Matthews C; Jia J; Collins I; White A; Burdett L; Hutchinson A; Qi L; Bacior JA; Lonsberry V; Rodesch MJ; Jeddeloh JA; Albert TJ; Halvensleben HA; Harkins TT; Ahn J; Berndt SI; Chatterjee N; Hoover R; Thomas G; Hunter DJ; Hayes RB; Chanock SJ; Amundadottir L
Hum Genet; 2010 Jan; 127(1):91-9. PubMed ID: 19823874
[TBL] [Abstract][Full Text] [Related]
9. Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins.
Jansen FH; Roobol M; Jenster G; Schröder FH; Bangma CH
Eur Urol; 2009 Mar; 55(3):563-74. PubMed ID: 19058905
[TBL] [Abstract][Full Text] [Related]
10. Percent free PSA as an additional measure in a prostate cancer screen.
Miele ME
Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
[TBL] [Abstract][Full Text] [Related]
11. Aggressiveness of inflammation in histological prostatitis--correlation with total and free prostate specific antigen levels in men with biochemical criteria for prostate biopsy.
Stimac G; Reljic A; Spajic B; Dimanovski J; Ruzic B; Ulamec M; Sonicki Z; Kraus O
Scott Med J; 2009 Aug; 54(3):8-12. PubMed ID: 19725275
[TBL] [Abstract][Full Text] [Related]
12. Blood biomarker levels to aid discovery of cancer-related single-nucleotide polymorphisms: kallikreins and prostate cancer.
Klein RJ; Halldén C; Cronin AM; Ploner A; Wiklund F; Bjartell AS; Stattin P; Xu J; Scardino PT; Offit K; Vickers AJ; Grönberg H; Lilja H
Cancer Prev Res (Phila); 2010 May; 3(5):611-9. PubMed ID: 20424135
[TBL] [Abstract][Full Text] [Related]
13. Predictors of prostate cancer on repeat prostatic biopsy in men with serum total prostate-specific antigen between 4.1 and 10 ng/mL.
Okegawa T; Kinjo M; Ohta M; Miura I; Horie S; Nutahara K; Higashihara E
Int J Urol; 2003 Apr; 10(4):201-6. PubMed ID: 12657099
[TBL] [Abstract][Full Text] [Related]
14. Comparisons of the various combinations of free, complexed, and total prostate-specific antigen for the detection of prostate cancer.
Okegawa T; Noda H; Nutahara K; Higashihara E
Eur Urol; 2000 Oct; 38(4):380-7. PubMed ID: 11025374
[TBL] [Abstract][Full Text] [Related]
15. Comparison of two investigative assays for the complexed prostate-specific antigen in total prostate-specific antigen between 4.1 and 10.0 ng/mL.
Okegawa T; Noda H; Nutahara K; Higashihara E
Urology; 2000 May; 55(5):700-4. PubMed ID: 10792084
[TBL] [Abstract][Full Text] [Related]
16. Genome-wide association study identified novel genetic variant on SLC45A3 gene associated with serum levels prostate-specific antigen (PSA) in a Chinese population.
Sun J; Tao S; Gao Y; Peng T; Tan A; Zhang H; Yang X; Qin X; Hu Y; Feng J; Kim ST; Lin X; Wu Y; Zhang J; Li Z; Li L; Mo L; Liang Z; Shi D; Huang Z; Huang X; Liu M; Liu Q; Zhang S; Lilly Zheng S; Xu J; Mo Z
Hum Genet; 2013 Apr; 132(4):423-9. PubMed ID: 23269536
[TBL] [Abstract][Full Text] [Related]
17. The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/mL.
Stephan C; Stroebel G; Heinau M; Lenz A; Roemer A; Lein M; Schnorr D; Loening SA; Jung K
Cancer; 2005 Sep; 104(5):993-1003. PubMed ID: 16007682
[TBL] [Abstract][Full Text] [Related]
18. Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade.
Haese A; Vaisanen V; Lilja H; Kattan MW; Rittenhouse HG; Pettersson K; Chan DW; Huland H; Sokoll LJ; Partin AW
J Urol; 2005 Mar; 173(3):752-6. PubMed ID: 15711262
[TBL] [Abstract][Full Text] [Related]
19. The prognostic value of different forms of prostate specific antigen and their ratios in patients with prostate cancer.
Björk T; Lilja H; Christensson A
BJU Int; 1999 Dec; 84(9):1021-7. PubMed ID: 10571627
[TBL] [Abstract][Full Text] [Related]
20. Age-specific reference ranges for prostate-specific antigen (PSA) in Jordanian patients.
Battikhi MN
Prostate Cancer Prostatic Dis; 2003; 6(3):256-60. PubMed ID: 12970732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
